title: Catecholaminergic based therapies for functional recovery after TBI.
abstract: Among the many pathophysiologic consequences of traumatic brain injury are changes in catecholamines, including dopamine, epinephrine, and norepinephrine. In the context of TBI, dopamine is the one most extensively studied, though some research exploring epinephrine and norepinephrine have also been published. The purpose of this review is to summarize the evidence surrounding use of drugs that target the catecholaminergic system on pathophysiological and functional outcomes of TBI using published evidence from pre-clinical and clinical brain injury studies. Evidence of the effects of specific drugs that target catecholamines as agonists or antagonists will be discussed. Taken together, available evidence suggests that therapies targeting the catecholaminergic system may attenuate functional deficits after TBI. Notably, it is fairly common for TBI patients to be treated with catecholamine agonists for either physiological symptoms of TBI (e.g. altered cerebral perfusion pressures) or a co-occuring condition (e.g. shock), or cognitive symptoms (e.g. attentional and arousal deficits). Previous clinical trials are limited by methodological limitations, failure to replicate findings, challenges translating therapies to clinical practice, the complexity or lack of specificity of catecholamine receptors, as well as potentially counfounding effects of personal and genetic factors. Overall, there is a need for additional research evidence, along with a need for systematic dissemination of important study details and results as outlined in the common data elements published by the National Institute of Neurological Diseases and Stroke. Ultimately, a better understanding of catecholamines in the context of TBI may lead to therapeutic advancements. This article is part of a Special Issue entitled SI:Brain injury and recovery.
authors.affiliation: Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA 15213, USA; School of Nursing, University of Pittsburgh, Pittsburgh, PA 15213, USA.
authors.forename: Nicole D
authors.initials: ND
authors.lastname: Osier
authors.affiliation: Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA 15213, USA; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA 15260, USA; V.A. Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA. Electronic address: dixonec@upmc.edu.
authors.forename: C Edward
authors.initials: CE
authors.lastname: Dixon
mesh_terms: D000818:Animals; D000070642:Brain Injuries, Traumatic / Q000188:drug therapy* / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017983:Receptors, Catecholamine / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D020127:Recovery of Function / Q000187:drug effects* / Q000502:physiology*
chemical_list: D002395:Catecholamines; D018696:Neuroprotective Agents; D018377:Neurotransmitter Agents; D017983:Receptors, Catecholamine
keywords: Catecholamine; Dopamine; Epinephrine; Norepinephrine; Therapy; Traumatic brain injury